OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

Summary by AI BETAClose X

OKYO Pharma announced its participation in upcoming ophthalmic scientific conferences, including Eyecelerator on October 8, 2026, where the CEO will present on addressing unmet needs in corneal and anterior segment diseases. The company will also engage with experts at the American Academy of Optometry and the American Academy of Ophthalmology. This presence underscores OKYO's commitment to engaging with both optometrists and ophthalmologists regarding neuropathic corneal pain (NCP). Furthermore, OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP treatment.

Disclaimer*

UK 100

Latest directors dealings